|Other Names||Cyclin-L1, Cyclin-L, CCNL1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6610b was selected from the C-term region of human CCNL1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Involved in pre-mRNA splicing. Functions in association with cyclin-dependent kinases (CDKs) (PubMed:18216018). Inhibited by the CDK-specific inhibitor CDKN1A/p21 (PubMed:11980906). May play a role in the regulation of RNA polymerase II (pol II). May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC) (PubMed:12414649, PubMed:15700036).|
|Cellular Location||Nucleus speckle. Nucleus, nucleoplasm. Note=Found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing.|
|Tissue Location||Widely expressed. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC)|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CCNL1 is a transcriptional regulator which participates in regulating the pre-mRNA splicing process. The protein seems to be involved in the regulation of RNA polymerase II (pol II). It functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. It may be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.
Loyer,P., J. Biol. Chem. 283 (12), 7721-7732 (2008)Herrmann,A., FASEB J. 21 (12), 3142-3152 (2007)
If you have any additional inquiries please email technical services at email@example.com.